Federal Court Ruling Allows State to Sue Pfizer for Deceptive Marketing Practices
A federal judge in Kansas (State of v. Pfizer Inc. (Case No. 6:2024cv01128) from May 14, 2025) has ruled that the state can proceed with its lawsuit against pharmaceutical giant Pfizer, accusing the company of engaging in deceptive marketing practices related to its COVID-19 vaccine. This ruling marks a significant development in the ongoing legal scrutiny of Big Pharma’s conduct during the COVID-19 pandemic. The case, led by Kansas Attorney General Kris Kobach, centers on allegations that Pfizer misled the public about the safety and efficacy of its vaccine, violating the Kansas Consumer Protection Act. This first-of-its-kind ruling could set a precedent for similar lawsuits in other states, challenging the legal protections often afforded to pharmaceutical companies under federal law.
Background of the Lawsuit
The lawsuit was initially filed in June 2024 in Thomas County, Kansas, by Attorney General Kris Kobach, who accused Pfizer of making false and misleading claims about its COVID-19 vaccine. The state alleges that Pfizer’s marketing campaign promoted the vaccine as “safe and effective” while downplaying or concealing known risks, including serious adverse events such as myocarditis, pericarditis, failed pregnancies, and deaths. According to the complaint, Pfizer’s actions constituted a “misinformation campaign” that violated consumer protection laws by promoting “false, misleading, and deceptive” statements.
Kansas is not alone in its legal pursuit. At least five other states, including Texas, have filed similar lawsuits against Pfizer, accusing the company of deceptive trade practices. These state-level actions highlight a growing movement to hold pharmaceutical companies accountable for their marketing practices, particularly when public trust in medical interventions is at stake. The Kansas case garners significant attention due to its progression to state court, overcoming Pfizer’s attempt to have the case dismissed or moved to federal jurisdiction.
The Federal Court Ruling
The ruling by U.S. District Court Judge Daniel D. Crabtree is a pivotal moment in the case. Pfizer argued that the lawsuit should be dismissed or handled in federal court, citing federal protections for vaccine manufacturers under the Public Readiness and Emergency Preparedness (PREP) Act. The PREP Act, enacted in 2005, grants immunity to companies producing countermeasures during public health emergencies, shielding them from liability for injuries or deaths caused by their products. However, Judge Crabtree ruled that Kansas’ claims focus on deceptive marketing practices, not physical injuries or deaths, and thus fall outside the scope of the PREP Act’s protections. This distinction allows the case to proceed in state court, where consumer protection laws provide a stronger framework for addressing deceptive advertising.
The ruling is being hailed as a major victory by advocates who want Pfizer to be held accountable. The decision underscores a critical legal nuance: while federal law may shield vaccine manufacturers from liability for physical harm, state consumer protection laws can still be used to challenge misleading marketing and opening for Kansas to pursue monetary penalties and injunctive relief against Pfizer.
Allegations Against Pfizer
The core of Kansas’ lawsuit revolves around claims that Pfizer knowingly misrepresented the safety and efficacy of its COVID-19 vaccine. Pfizer made statements suggesting the vaccine was 100% effective, despite early evidence of breakthrough infections and waning immunity over time. The state also alleges that Pfizer concealed data linking the vaccine to serious adverse events. These claims were allegedly designed to mislead consumers and healthcare providers, encouraging widespread vaccine uptake under false pretenses.
Attorney General Kobach has emphasized that the lawsuit is not about denying the vaccine’s role in combating COVID-19 but about ensuring transparency and accountability. Kobach stated in a pressconference in June 2024 that Pfizer made multiple misleading statements to deceive the public. He argues that the company’s actions eroded public trust in medical institutions and violated the Kansas Consumer Protection Act, which prohibits false or misleading representations in the sale of goods or services.
Far-reaching implications
The Kansas ruling has far-reaching implications for both the pharmaceutical industry and public health policy. By allowing the case to proceed in state court, the decision weakens the federal immunity shield that has long protected vaccine manufacturers. This could embolden other states to pursue similar lawsuits, particularly as public skepticism about COVID-19 vaccines and strong resentment against the industry and its too powerful influence over politics grows. During the COVID-19 pandemic, pharmaceutical companies like Pfizer were granted significant leeway to expedite vaccine development and distribution. This leniency allowed companies to prioritize profits over transparency, leading to overstated claims about vaccine safety and efficacy while politicians and state officials fought hard to silence anyone questioning it.
Pfizer has denied the allegations, asserting that its marketing practices complied with regulatory standards and that its vaccine underwent rigorous testing. The company has pointed to approvals from the U.S. Food and Drug Administration (FDA) and other global health authorities as evidence of its vaccine’s safety and efficacy. Pfizer also argues that the PREP Act should shield it from state-level lawsuits, a position that Judge Crabtree rejected in this case.
This is not the first time Pfizer has faced accusations of deceptive marketing. In 2009, the company paid $33 million to settle claims from multiple states, including Kansas, over unfair and deceptive marketing practices related to its drug promotion. More recently, in 2022, Kansas residents received over $85,000 as part of a settlement addressing Pfizer’s deceptive copayment coupon program. These prior settlements suggest a pattern of scrutiny over Pfizer’s marketing practices, which the current lawsuit builds upon.
Corporate accountability is absolutely essential. Even in times of crisis.
